Market research

PLYX Polaryx Therapeutics, Inc. Common Stock

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market cap: 103M
P/E ratio: Not available
Analyst target: 7.5
Dividend yield: Not available
Beta: Not available

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US73110F1003
Market cap: 103M
P/E ratio: Not available
Analyst target: 7.5
Dividend yield: Not available
Beta: Not available

About

About Polaryx Therapeutics, Inc. Common Stock

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about PLYX.

PLYX Polaryx Therapeutics, Inc. Common Stock

Price & volume

Company facts

About Polaryx Therapeutics, Inc. Common Stock

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet